The high prevalence of herpes simplex virus 2 (HSV-2) infections in humans necessitates the development of a safe and effective vaccine that will need to induce vigorous T-cell responses to control viral infection and transmission. We designed rAd-gD2, rAd-gD2DUL25, and rAd-DUL25 to investigate whether recombinant replication-defective adenoviruses vaccine could induce specific T-cell responses and protect mice against intravaginal HSV-2 challenge compared with FI-HSV-2. In the present study, recombinant adenovirus-based HSV-2 showed higher reductions in mortality and stronger antigen-specific T-cell responses compared with FI-HSV-2 and the severity of genital lesions in mice immunized with rAd-gD2DUL25 was significantly decreased by eliciting IFN-g-secreting T-cell responses compared with rAd-gD2 and rAd-DUL25 groups. Our results demonstrated the immunogenicity and protective efficacy of recombinant adenovirus vaccines in acute HSV-2 infection following intravaginal challenge in mice.
Herpes simplex virus type 2 is a sexually transmitted pathogen worldwide. The currently available body of evidence suggests that only widespread use of an effective vaccine can control the spread of herpes infection. Related studies strongly suggest that T-cell immunity is required to inhibit the replication and spread of HSV-2 to the nervous system and for longterm protection from recurrent infection (1) . Clearance of virus mediated by cellular immunity greatly depends on cytokine-mediated effector mechanisms. Specifically, cytokines secreted by Th1 CD4 þ T cells have been recognized to be responsible for HSV-2 clearance from vaginal mucosae. One of the most efficient approaches to enhance T-cell immunity is developing a virus-based vaccine. To date, recombinant Ad5 vectors are considered promising vaccine delivery modalities as they can induce potent transgene product-specific antibody and T-cell responses.
gD2, an accessory fusion protein required for membrane fusion by HSV, is a major target of neutralizing antibodies and antibody-dependent cellular cytotoxicity (2) (3) (4) . UL25 ORF encodes a capsid protein that is located in the viral capsid vertices and is associated with pentons (5) . A set of T-cell epitopes from HSV-2 UL25 was found capable of eliciting potent CD8 þ T-cell responses (6), whereas HSV-specific CD8 þ T-cell-mediated immune responses were deemed required for clearance of HSV from genital herpes lesions (7, 8) .
In this regard, we developed two recombinant replication-defective adenoviruses capable of expressing gD2 (rAd-gD2) and DUL25 (rAd-DUL25). In comparing the efficacy of the vaccine with FI-HSV2, the study showed that only rAd-gD2 provided significantly enhanced protective effects against vaginal challenge in mice. We also developed a recombinant replicationdefective adenovirus capable of expressing gD2 and truncated UL25 (DUL25) fusion protein (rAdgD2DUL25). We investigated whether DUL25 could induce specific T-cell responses and protect mice against intravaginal HSV-2 challenge. The results suggested that the UL25 antigen reduced genital lesions by enhancing T-cell responses. These findings support that a highly efficacious HSV-2 vaccine will need to induce a more vigorous T-cell response. Moreover, viral-vectored vaccines may be good candidates for the control of HSV-2 infection.
MATERIALS AND METHODS

Vaccines
FI-HSV2 preparation
HSV-2 strain G (cat# VR-734; ATCC, Manassas, VA, USA) was propagated by infection of confluent Vero cell (African green monkey kidney cells, cat# CCL-81; ATCC) monolayers at a MOI of 0.1, incubation at 34°C for 72 hr, and then harvesting of the cell-associated virus as previously described (9) . Pelleted virions were then treated with 0.1% formalin for 3 days at 37°C. Successful inactivation of HSV-2 was confirmed by its inability to produce CPE when incubated with Vero cells. The protein content was measured by a Bradford protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Preparation of recombinant adenoviruses
A human codon-optimized nucleotide sequence was derived from the HSV-2 HG52 amino acid sequence (Genbank accession number: Z86099.2). The gD2DUL25 fusion gene fragment, including a flexible peptide (Gly4Ser) 3 linker gene was synthesized. The truncated UL25 gene encodes amino acids 310 to 585, whereas the gD2 gene encodes amino acids 26 to 306. The gD2 gene, DUL25 and gD2DUL25 fusion gene were each cloned into the shuttle plasmid vector pDC316. Recombinant, replication-defective rAd-DUL25, rAd-gD2 and rAdgD2DUL25 were created using the AdMax Adenovirus Creation Kit (Microbix Biosystems, Inc., Mississauga, ON, Canada) according to the manufacturer's recommended protocol. Adenovirus Blank is an Ad5 vector containing an E1/E3 deletion (Newgene, Inc., Shanghai, China). The rAd-gD2DUL25, rAd-gD2 and rAd-DUL25 viruses were propagated in HEK293 cells (human embryonic kidney 293, cat# CRL-1573; ATCC) and purified by CsCl gradient centrifugation.
Expression of recombinant virus
PCR and Western blot assays were used to verify the presence of gD2, DUL25 and gD2DUL25. HEK293 cells were harvested when most cells showed CPE, and the lysates were obtained by freeze-thawing cells twice. Proteins from cell extracts were determined by Western blotting. Expressed antigens (gD2, UL25, gD2DUL25) were separated by electrophoresis on 13.5% SDS-PAGE under denaturing conditions and then transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The gD2 polyclonal antibody produced by our laboratory and 1:1000 anti-HA tag antibody (Abcam, Inc., Shanghai, China,) were used for Western blot assays. The viral stocks were then dialyzed and stored in aliquots at 80°C until use. The infectious titer (pfu/mL) was determined by TCID 50 assay using HEK293 cells.
Mice
Female BALB/c mice, 6-8 weeks of age were obtained from the Experimental Animal Center at Jilin University. All animal care and procedures conformed to guidelines of the Institutional Animal Care and Use Committee.
Immunizations and vaginal HSV-2 challenge model
The mice in test groups were immunized i.m. with 10 8 pfu rAd-gD2, rAd-DUL25 or rAd-gD2DUL25. Another group of mice was immunized with FI-HSV2 s.c. with 12.5 mg, whereas control mice received PBS. Each group was immunized three times and the interval between vaccinations was 14 days. Two weeks after the last immunization, all mice were challenged intravaginally with 2 Â 10 5 pfu. Six days prior to challenge, mice were injected s.c. with 2 mg Depo Provera (Pharmacia Upjohn, Kalamazoo, MI, USA). Mice were monitored and pathological developments were scored daily for 20 days post-challenge. Disease scoring was as follows: 0, no visible lesions; 1, redness or swelling; 2, skin lesions or hair loss; 3, urine and fecal retention and hindlimb paralysis; 4, moribund. A nylon-tipped applicator was used to collect vaginal secretions every 2 days for 12 days post-challenge, and the swabs were stored at À80°C until analysis. All immunization and challenge experiments were repeated three times.
Antibody quantification
gD-specific immunoglobulin G ELISA The gD protein was expressed as a recombinant C-terminal His-tagged protein from Escherichia coli and purified using the Ni-NTA Purification System (Invitrogen, Carlsbad, CA, USA) under denaturing conditions. Ninety-six-well plates were coated with HSV-2 gD at 100 ng per well in 0.05 M carbonate-bicarbonate buffer (pH 9.6) overnight at 4°C. Titer of gD-specific immunoglobulin (Ig)G was tested by ELISA assay as previously described (10) . The plates were finally developed using a TMB (Sigma, St Louis, MO, USA) substrate solution and read at 450 nm. The antibody titer was defined as the reciprocal of the highest dilution that gave an absorbance at least twice that produced by the negative control.
Neutralizing antibody assay
The neutralizing activity of each immune serum sample was tested by a micro-neutralization assay as previously described (11) . Briefly, the serum samples were heated at 56°C for 30 min. HSV-2 strain G (200 pfu, cat# VR-734; ATCC) stock was mixed with two-fold serially diluted serum starting at 1:20 dilution. The neutralizing titer was defined as the highest serum dilution for which no CPE were detected.
ELISPOT assays
Blood samples for IFN-g Enzyme-Linked ImmunoSpot (ELISPOT) assays were drawn 2 weeks after the last immunization. Briefly, 96-well filter plates were precoated with 5 mg/mL purified anti-mouse IFN-g mAb overnight at 4°C. Thereafter, splenocytes were added to the wells (1 Â 10 6 cells/well) with the HSV-2 gD 53-65 (LTDPPGVKRVYHI) (12) or UL25 363-372 (FLARGHNLF) peptide (5 mg/mL) and incubated for 24 hr at 37°C. UL25 363-372 was chosen based on CD8 þ T-cell epitope mapping of UL25 and were predicted to bind to H-2 d MHC class I molecules using the SYFPEITHI algorithm (Institute for Cell Biology, Heidelberg, Germany). Spots were developed in accordance with the manufacturer's protocol (BD Biosciences, Franklin Lakes, NJ, USA). Results were expressed as the number of spot-forming cells (SFC) per 10 6 splenocytes.
Multiplexed microsphere cytokine assay
Splenocyte suspensions were added to a sterile 96-well round bottom plate (1 Â 10 7 cells/well) and incubated for 72 hr with 2.5 mg gD . The supernatants were collected, and their Th1/Th2 cytokine contents were analyzed using a cytokine multiplex bead-based assay (Bio-Rad Mouse Cytokine Th1/Th2 Assay) according to the manufacturer's instructions. Cytokine levels in the culture supernatant were quantitated by analyzing 100 mL of each sample on the Luminex 1 100 IS TM System (Luminex Corporation, Austin, TX, USA).
Real-time quantitative PCR detection of viral DNA
DNA of each sample was obtained using a DNA extraction Kit (Qiagen, Hilden, Germany). HSV-2 loads in vaginal swabs were determined by qPCR targeting the HSV-2 gG gene. Specific primers used for gG2 DNA were as follows: forward, 5 0 -CCCACACCCCAACACATC-3 0 ; and reverse, 5
0 -CCAAGGCGACCAGACAAAC-3 0 (13). Ten-fold dilutions of the gG2-T Easy recombinant plasmid was used as the PCR standard template to quantify the HSV-2 copy number in the samples. Target DNA was detected by qPCR with SYBR green dye (Sigma, St. Louis, MO, USA) under conditions of 30-s denaturation at 94°C followed by 40 two-step amplification cycles (5 s at 94°C, 30 s at 63°C). PCR products were analyzed with the Bio-Rad CFX Manager TM , version 2.1. Vaginal swab samples were considered negative if they contained <5 copies of HSV-2 DNA per assay.
Statistical analysis
Data for each assay were compared by ANOVA and Student's t-test using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). Survival results were evaluated using the long-rank test. All tests were threetailed, and a P-value <0.05 was considered to indicate a significant difference.
RESULTS
Expression of recombinant proteins
Western blot analysis was carried out to characterize gD2DUL25, gD2 and DUL25 protein expression in extracts of HEK293 cells (Fig. 1 ) using gD polyclonal antibody and a HA-tagged mouse monoclonal antibody as the primary antibody. A band of approximately 65 kDa was visualized that represented the gD2DUL25 protein (Fig. 1a, lane 1) , a band of approximately 31 kDa was detected that represented the gD2 protein ( Fig. 1b lane 2) , and the other band of approximately 33 kDa was detected that represented the DUL25 protein ( Fig. 1c lane 2) . These results indicated that the rAd-gD2DUL25, rAd-gD2 and rAd-DUL25 viruses were propagated in HEK293 cells, and all recombinant proteins were expressed intracellularly.
Antibody responses
Total serum IgG response against the gD2 antigen was measured by ELISA using blood samples collected from eight mice of each immunization group 2 weeks after the last vaccine dose (Fig. 2a) . Three groups: rAd-gD2, rAd-gD2DUL25 and FI-HSV2 triggered significantly higher levels of systemic gD2-specific IgG than negative control animals (PBS) or rAd-DUL25. Immunization with rAd-gD2 and rAd-gD2DUL25 could elicit strong gD2-specific IgG levels, which were significantly higher than that with FI-HSV2. Levels of virus-neutralizing antibody were measured by CPE reduction assay. rAd-DUL25 did not elicit any neutralizing antibody titers against HSV-2, but FI-HSV2, rAd-gD2 and rAdgD2DUL25 elicited similar neutralizing antibody titers against HSV-2 (Fig. 2b) .
ELISPOT analysis of IFN-g responses
IFN-g is important for immune protection against genital herpes infection by enhancing T-cell-mediated clearance mechanisms in mice (14) . To assess IFN-gsecreting T-cell responses, gD 53-65 and UL25 364-372 T-cell epitopes were used in the ELISPOT assays. As shown in Figure 3 , BALB/c mice vaccinated with rAd-DUL25 generated a level of gD 53-65 -specific IFN-g-secreting T cells that was similar with PBS, BALB/c mice vaccinated with FI-HSV2 generated only a marginal level of gD 53-65 -specific IFN-g-secreting T cells, whereas the rAd-gD2 and rAd-gD2DUL25 groups had significantly higher numbers of these cells. The two rAd vaccinated groups, rAd-gD2 and rAd-gD2DUL25, had similar levels of IFNg-producing T cells restricted to the gD 53-65 epitope. More importantly, IFN-g-secreting splenocytes stimulated with all peptides in the rAd-gD2DUL25 group reached remarkably high levels.
Cytokine multiplex bead assay of Th1-type and Th2-type cytokines
To understand the immune profile induced by the various vaccines, we examined both Th1 (IL-2 and IFN-g) and Th2 (IL-4 and IL-10) cytokine levels in the four groups by using a multiplex bead assay. With the rAd-gD2 vaccine, IL-2, IFN-g and IL-4 production significantly increased (P < 0.001), whereas IL-10 The neutralization titer was defined as the reciprocal value of the highest serum dilution for which there was no CPE. Data are presented as the mean AE SEM of 10 mice from each group.
ÃÃÃ P < 0.001; ÃÃ P < 0.01; Ã P < 0.05.
increased marginally (P < 0.05), which indicated a Th1-biased immune response, compared with control mice. With the rAd-DUL25 vaccine, IL-2, IFN-g production increased (P < 0.001), whereas IL-10, IL-4 increased marginally (P < 0.05), which indicated a Th1-biased immune response, compared with control mice. The FI-HSV2 vaccine significantly increased IL-2, IL-4 production, but only marginally increased IFN-g and IL-10, compared with control immunization. The rAdgD2DUL25 vaccine increased IL-2 and IFN-g production, whereas it only slightly increased IL-4 and IL-10 levels, compared with control mice (Fig. 4) . No significant levels of IL-12 (p70) or TNF-a could be detected for any of the groups (data not shown). Taken together, our results showed that immunization with rAd-gD2 and rAd-gD2DUL25 could induce higher Th1-type T-cell responses, whereas FI-HSV2 could induce higher Th2-type T-cell responses.
Protection against vaginal HSV-2 challenge
Mice of all groups were challenged intravaginally with 2 Â 10 5 PFU of HSV-2 strain G, and their disease symptoms were monitored daily for 20 days. As shown in Figure 5a , animals that had received PBS and rAd-DUL25 showed only progressive disease symptoms starting on day 2 after challenge, and all of these mice were killed as a result of neurological disease manifestations at day 8. A single vaccination with FI-HSV2 generated a protection rate of 50% against vaginal challenge in mice. In comparison to the FI-HSV2 group, immunization with rAd-gD2 showed little mortality with 62.5% of mice surviving 18 days post-challenge, whereas rAd-gD2DUL25 showed a higher survival rate up to 75%.
Severity of disease scores observed in the rAdgD2DUL25 group were much lower than in the other groups (P < 0.001) (Fig. 5c) . Control animals experienced significantly more severe symptoms than did mice in all three immunization groups after vaginal challenge. Severe vaginal pathological signs were observed in the FI-HSV2-and rAd-gD2-vaccinated mice. Additionally, viral titers measured in the vaginal swabs from days 2, 4, 6, 8, 10 and 12 post-infection showed that the amounts of vaginal swab HSV-2 viral DNA were significantly reduced in all three vaccinated groups compared with control immunization at day 7 post-challenge (Fig. 5b) , with the lowest amount of viral DNA detected in rAdgD2DUL25-vaccinated mice (P < 0.001). There was no significant difference between the rAd-gD2 group and the FI-HSV2 group with vaginal HSV-2 DNA copies (P > 0.05).
DISCUSSION
The effect of T-cell responses has been emphasized in recent reports. Having a vaccine that elevates T-cellbased immune responses is essential, but a neutralizing antibody response may also be helpful. Indeed, the clever immune-evasion strategies adopted by the virus would require stronger humoral responses as well as enhanced cell-mediated immunity (15, 16) . To date, whether humoral or cell-mediated responses are more relevant to protection against HSV2 has not been determined definitively. In the present study, we attempted to construct a recombinant adenovirus vaccine to investigate whether an enhanced T-cell response could improve the protection of the vaccine. During the past few years, recombinant live-attenuated or replicationdeficient viruses have been extensively developed as vaccine platforms, and many viral vector-based vaccines have been licensed for animals (17) . Viral-vectored vaccines can induce systemic T-cell responses, including polyfunctional cytokine-secreting CD4 þ and CD8 þ T cells. Considering the well-established properties of adenovirus vectors in eliciting both CD4 þ T and CD8 þ T cells in vaccine protocols (18) (19) (20) , we designed recombinant replication-defective adenoviruses to deliver gD2 alone, DUL25 alone or the gD2DUL25 fusion and compared their immunogenicities with that of FI-HSV2 as described by Morello et al. (9) . As demonstrated in our study, both the rAd-gD2 and rAd-gD2DUL25 vaccines provided better protection than the FI-HSV2 vaccine in BALB/c mice challenged intravaginally with HSV-2, whereas rAd-DUL25 did not show this enhanced effect. The recombinant adenovirus vaccines conferred much greater survival rates and significantly elevated IFN-g and IL-2 levels. The results demonstrated that the recombinant adenovirus vaccines could stimulate strong Th1-type cellular immunity. Several investigators have observed that IFN-g is important for resolution of lesions and clearance of HSV-2 genital infections (21), and IL-2 has been shown to be secreted within a few hours after CD8 þ T-cell activation (22) . However, we observed higher levels of IL-4 and IL-10 (Th2-type cytokines) in mice immunized with FI-HSV2 compared to those given the recombinant adenoviruses, suggesting that Th2 immune responses contributed less to the protection against HSV-2.
The well-known gD2-Alum-MPL subunit vaccine developed by GlaxoSmithKline (Brentford, UK) demonstrated that it could induce potent humoral and T-cell responses for complete protection against primary disease in the guinea-pig model (23) , but insufficient protection with this vaccine was observed in humans (24) . These results suggested that focus should be placed on a specific subset of viral antigens to enhance T-cell responses in further development of HSV-2 vaccines. Lawrence Corey and colleagues suggested that UL25 is one of the most frequently recognized HSV-2-specific CD8þ T-cell epitopes in HSV-2 seropositive individuals (6, 25) and may be a potent immunogen for conferring protective immunity. To investigate whether UL25 could enhance T-cell responses of rAd-gD2 and protect mice against intravaginal HSV-2 challenge, we constructed a rAd-gD2DUL25 vaccine. Because of the insertion capacity of the recombinant adenovirus, we used a truncated form of the HSV-2 UL25 protein containing immunodominant T-cell epitopes. Residues 310 to 585 of the UL25 antigen have been shown to contain T-cell epitopes which elicit CD8þ T-cell proliferation and production of inflammatory cytokines (25) . Although the mice immunized with rAd-gD2DUL25 lacked a significant difference in mortality rates, the severity of genital lesions was significantly decreased compared with the mice immunized with rAd-gD2 in the present study. We also assessed mucosal infection by measuring shedding of virus after challenge and found that viral genomic copy numbers in the rAd-gD2DUL25 group had the largest reduction among all immunization groups at day 8 post-challenge. Results of the IFN-g ELISPOT assay acquired by stimulation of splenocytes with the gD 53-65 peptide known to generate IFN-g-producing T cells indicated a significantly greater response in mice immunized with rAd-gD2DUL25 and rAd-gD2. We also successfully characterized the sequence FLARGHNLF (UL25 364-372 ) as a dominant T-cell epitope in UL25. This peptide stimulated strongly and specifically IFN-g-producing T cells of mice immunized with rAd-gD2DUL25 in the ELISPOT assay. These results indicate that the HSV-2-specific T-cell-mediated immune response generated by gD2 plays an important role in protection against HSV-2 disease and the HSV-2-specific T-cell-mediated immune response generated by UL25 is reversely correlated with severity of mouse genital disease.
Antibodies can protect humans against central nervous system infection (26) , and recombinant adenoviruses have been shown to elicit robust antigen-specific serum IgG antibody responses to transgenes (27) . In our study, we developed recombinant replication-defective adenoviruses to deliver gD2 alone, DUL25 alone or the gD2DUL25 fusion protein for comparison with FI-HSV2 in terms of immunogenicity and protective efficacy against HSV-2 challenge. However, the differences in protection among animals vaccinated with recombinant adenovirus vaccines and inactivated vaccine could not be explained by induced neutralizing antibodies, as the titers induced by those vaccines were not significantly different.
In the present study, neutralizing antibody responses were found to be higher in the combined gD2DUL25 fusion protein group compared to the gD2-alone group (Fig. 2b) . The IFN-g response induced by the gD2DUL25 fusion protein group was higher than those of the gD2 alone and DUL25 alone groups, either following gD2 stimulation or UL25 stimulation (Fig. 3) . As shown in several previous reports, the fusion protein antigens could induce higher immune responses than could be obtained with separate antigen proteins or a mixture of the two antigen proteins (28, 29) . These results indicated that the expression of the fusion protein may induce certain cytokines to promote both humoral and cellular immunity and should be analyzed in greater depth in future work.
In previous reports, gD2 subunit vaccine with ideal adjuvants indeed introduced protection to a certain extent in animal models by inducing high-level humoral immune response. In this study, although T-cell responses were induced by the recombinant adenovirus rAdgD2DUL25, protection was not nearly as good as the gD2 subunit vaccine produced in the mouse model. This might be attributed to several reasons. First, both gB2 and gD2 serve essential roles in virus entry and are expressed on the virus envelope, making them accessible to neutralizing antibodies (30) . Second, for pathogens that infect at mucosal surfaces, correlates of protection may involve locally produced IgA antibodies or IgG that reaches the mucosal surface by transcytosis from serum (31) . Thus, in future work, we might enhance the vaccine's protective ability by antigen optimization and immunization route, such as using both gB and gD as antigen or using intranasal immunization to enhance mucosal protection.
The utility of rAd5 vectors may be limited by the high prevalence of pre-existing anti-Ad5 immunity in human populations. However, this limitation may be overcome to a large extent by using heterologous priming strategies (32) or novel rAd vectors derived from rare Ad serotypes (33) . These approaches deserve further study in HSV-2 clinical studies in which it will be possible to analyze the specific immune exposures of diverse human subjects.
In summary, the present study demonstrated the immunogenicity and protective efficacy of recombinant adenovirus vaccines in acute HSV-2 infection following intravaginal challenge in mice. The recombinant adenovirus-based HSV-2 vaccines stimulated HSV-2 specific T cells to produce high levels of IFN-g and IL-2. The results supported the rationale that cellular immunity response plays a key role in protection from HSV-2 disease. UL25 could elicit T-cell responses, but whether UL25 could be a target for HSV-2 vaccine therapy will be explored in subsequent studies.
